Program - SSSD2019
Wednesday April 10th
Registration (open from 10:00)
11.00 - 11.15 Opening with Welcome Remarks from the chair of the local organising committee
Malin Flodström-Tullberg
11.15 - 12.45 Session 1: Islet physiology and pathophysiology
Chair: Per-Ola Carlsson
Islet cell exocytosis in type 2 diabetes
Sebastian Barg, Uppsala University, Sweden
Diabetes from a cellular perspective
Lena Eliasson, Lund University, Sweden
Oral abstract presentations
Gonzalo Sanchez GABAergic signaling in the primary cilium of pancreatic islet β-
cells
12.45 - 14.15 Lunch & Exhibition
13.30 - 14.00 Lunch seminar on scientific publications
Mikael Rydén, Karolinska Institutet, co-editor of Diabetologia
14.15 - 15.30 Session 1: Islet physiology and pathophysiology (continued)
Chair: Valdemar Grill
Oral abstract presentations
Anders Tengholm Glucose-induced changes of α-cell cAMP control glucagon release during hypoglycaemia
Luis Rodrigo Cataldo PP1R1A, a novel regulator of the GLP1R-amplifying glucose stimulated insulin secretion in β-cells
Ruifeng Shi The expression and function of Clec11a in human islets
Hanna Liljebäck Fewer islets survive from first transplantation than second transplantation: evaluation of intraportal islet transplantation in mice
Anja Brboric Developing techniques for expansion and culture of neural crest stem cells isolated from human bone marrow to improve the survival and function of transplanted islets of Langerhans
Sara Ullsten Increased susceptibility for immune attack of highly blood perfused, highly metabolically active pancreatic islets
15.30 - 16.00 Coffee break and exhibition
16.00 - 17.00 Oral abstract presentations (continued)
Chair: Mikael Rydén
Type 1 diabetes – clinical aspects
Anna Korsgaard Berg The economic additional expenditure related to skin problems in patients using insulin pump and/or glucose sensor in a Danish context
Maarit K Koskinen Longitudinal pattern of first phase insulin response is associated with genetic factors outside class II HLA region in children with multiple autoantibodies
Anmol Kumar The association between FGF23 and bone mineral density in type 1 diabetes with different stages of renal disease
Fanny J Jansson High remnant cholesterol predicts progression of diabetic nephropathy in type 1 diabetes
Marika Eriksson Association between blood pressure measured ambulatory and cerebral small-vessel disease in type 1 diabetes
17.00 - 18.15 Knud Lundbeck Award lecture:
Chair: Björn Olav Åsvold
New insights into genetics of metabolic health and disease – lessons to be used in precision medicine
Torben Hansen, University of Copenhagen, Denmark
18.30 Welcome reception, exhibition
Thursday April 11th
08:30 - 09.45 Session 2: Imaging in diabetes
Chair: Joey Lau-Börjesson
Eyelets in diabetes research and clinic
Per-Olof Berggren, Karolinska Institutet, Sweden
Metabolic imaging of adipose tissue in diabetes
Kirsi Virtanen, University of Eastern Finland, Finland
09.45 - 10.45 Oral abstract presentations
Chair: Lena Eliasson
Infections and islet disease
Magdalena A Mazur Type III interferons (IFNλs) are expressed in the human type 1 diabetes pancreas at disease onset, upregulate HLA class I expression and protect beta cells from Coxsackievirus infection
Carmen Herrera Hidalgo Neonatal infections alter islet maturation and long-term glucose homeostasis
Kristel Parv Phagocytosis and efferocytosis by pancreatic macrophages
Virginia M Stone A hexavalent vaccine covering all Coxsackievirus B (CVB) serotypes protects against acute CVB infection and CVB-induced diabetes in mice
Isabel Diaz Lozano Identifying novel biomarkers for virus-induced diabetes using an experimental animal model
10.45 - 11.15 Coffee break and exhibition
11.15 - 12.00 The Swedish Child Diabetes Foundation's Johnny Ludvigsson Nordic Prize lecture:
Chair: Johnny Ludvigsson
Quality of care – the answer is blowing in the registries
Jannet Svensson, Copenhagen University Hospital, Denmark
12.00 - 12.45 The Swedish Child Diabetes Foundation's Johnny Ludvigsson
Prize to a Young Swedish Scientist lecture:
Chair: Johnny Ludvigsson
Beta-cell replacement in type 1 diabetes
Joey Lau Börjesson, Uppsala University, Sweden
12.45 - 14.00 Lunch and exhibition
13.30 - 14.00 Lunch seminar on academic innovations
Patrik Blomquist, KI Innovation, Stockholm, Sweden
14.00 - 15.15 Session 3: Pathophysiology and prevention of type 1 diabetes
Chair: Malin Flodström-Tullberg
Beta cell stress and development of Type 1 diabetes
Johnny Ludvigsson, Linköping University, Sweden
Viruses and type 1 diabetes - prospects for prevention
Heikki Hyöty, University of Tampere, Finland
15.15 - 15.45 Coffee break and exhibition
15.45 – 17.00 Oral presentations (two parallel sessions)
Hall 1 - Type 2 diabetes and LADA – clinical aspects
Chair: Daniel Andersson
Maria Houborg Petersen High intensity interval training combining biking and rowing markedly improves insulin sensitivity, body composition and VO2max
Maria Hornstrup Christensen Future health and gestational diabetes - the FUDGE study
Anna P Westberg The impact of maternal weight in pregnancy on glucose tolerance and insulin resistance in non-diabetic offspring
Sofia Carlsson Type 2 diabetes and occupation; professional drivers, manufacturing workers and cleaners are at high risk; evidence from all Swedish employees 2006-2015
Nikolaos Tertipis High-throughput metabolomics for early detection of individuals at increased risk for type 2 diabetes
Ingrid K Hals Insulin treatment vs. sitagliptin does not affect deterioration of insulin secretion in LADA patients. Results from a 21 month randomized study
Rebecka Hjort Physical activity and genetic susceptibility in relation to the risk of latent autoimmune diabetes in adults and type 2 diabetes
Hall 2 - Immunological aspects of type 1 diabetes
Chair: Johanna Lempainen
Louise Magnusson Identification of altered immune cell subsets in patients with autoimmune endocrine diseases by mass cytometry
Zhengkang Luo Kinetics of immune cell responses in the multiple low dose streptozotocin mouse model of type 1 diabetes
Fabricia Dietrich Immunological effects of GAD-alum injection into the lymph node in recent onset type 1 diabetes
Hugo Barcenilla Mass cytometry identifies regulatory T and Natural Killer cell subsets that are increased in individuals at high risk for type 1 diabetes
Camilla Skoglund Increased levels of neutrophil extracellular trap (NET) remnants as well as mitochondrial and nuclear DNA in newly diagnosed type 1 diabetes children
Kailash Singh Role of regulatory B cells in clinical and experimental type 1 diabetes
17.15 - 18.30 Session 4: Clinical Science and Care
Chair: Per-Ola Carlsson
Glucose sensor technologies in the management of type 1 diabetes
Jan Bolinder, Karolinska Institutet, Sweden
Insulin pumps, from simple injection aid to advanced technology
Anders Frid, Lund University, Sweden
18.30 – 19.15 General assembly of SSSD. Presentation of next year´s meeting
19.30 Congress Dinner World Trade Center
Friday April 12th
08:30 – 09:00 Session 4: Clinical Science and Care, continued
Chair: Per-Ola Carlsson
News from the Swedish National Diabetes Register (NDR)
Soffia Gudbjörnsdottir University of Gothenburg, Sweden
09.00 - 09.30 SSSD Young Investigator Awards
Chair: Björn-Olav Åsvold
Insulin secretion depends on intra-islet glucagon signaling
Berit Svendsen, University of Copenhagen, Denmark
Sodium glucose transporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
Peter Ueda, Karolinska Institutet, Sweden
09.30 - 10.45 Session 5: Metabolism and inflammation in type 2 diabetes
Chair: Anna Krook
Novo Nordisk Foundation Award Lecture:
Incretin therapy - Lessons learned and future directions
Bo Ahren, Lund University, Sweden
Human adipose tissue and metabolic health
Kirsty Spalding, Karolinska Institutet, Sweden
10.45 - 11.15 Coffee break (sponsored by AstraZeneca)
11.15 - 12.30 Session 6: Precision Medicine and Drug Discovery
Chair: Olov Andersson
Translational studies to enable tailored treatment of type 2 diabetes
Anders Rosengren. University of Gothenburg, Sweden
Towards the development of microfluidic multi-tissue models for diabetes research and drug discovery
Volker Lauschke, Karolinska Institutet, Sweden
12.30 - 12.45 Closing of the meeting
12.45 Lunch and farewell